NasdaqHealth CareHealth Care TechnologyS&P SmallCap 600
$12.05
-0.13 (-1.07%)
Close of Nov 06, 2026 · end-of-day data
CERT 8-K filings, explained
Every material Form 8-K Certara has filed with the SEC since February 26, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Certara reported third-quarter 2026 revenue of $94.9 million, up 4% from a year earlier, with software revenue up 11% and services revenue down 2%. The net loss from continuing operations narrowed to $3.6 million, and the company narrowed its full-year 2026 revenue growth range to 2% to 3% and updated its adjusted diluted EPS range to $0.31 to $0.34.
Q3 2026 revenue $94.9 million vs. $90.9 million in Q3 2025; software revenue $48.8 million (up 11%), services revenue $46.1 million (down 2%)
Net loss from continuing operations $3.6 million vs. $4.8 million a year earlier; adjusted EBITDA $30.2 million, up 6%
2026 full-year revenue growth range narrowed to 2% to 3%; adjusted diluted EPS outlook $0.31 to $0.34
Grant Peterson appointed Chief Product Officer, effective November 2, 2026
Certara reported second-quarter 2026 revenue of $93.3 million, up 1% from a year earlier, but swung to a continuing-operations net loss of $6.1 million from a $1.5 million profit. Total net loss attributable to common stockholders was $55.3 million, including a $49.2 million loss from discontinued operations tied to the divested Regulatory and Medical Writing business. The company reaffirmed its 2026 revenue growth guidance of 0% to 4%, while shareholders also received updated adjusted EBITDA margin and adjusted EPS guidance.
Software revenue rose 4% to $48.8 million, while services revenue fell 3% to $44.5 million.
Adjusted EBITDA was $26.2 million, down from $27.0 million; diluted loss per share from continuing operations was $(0.04) versus $0.01 a year earlier.
The company completed a $100 million share repurchase program and the board approved an additional $50 million.
Julien Perrier was appointed Chief Commercial Officer effective August 1, 2026.
Certara, Inc. said its President and Chief Commercial Officer, Leif E. Pedersen, left that role effective August 1, 2026. He will stay on as a Senior Advisor to help with transition matters until December 31, 2026, when his employment is set to end without cause and he becomes eligible for severance under his existing agreement and the company's Executive Officer Severance Policy.
Departure from President and Chief Commercial Officer role effective August 1, 2026
Senior Advisor role for transition matters through December 31, 2026
Employment to be terminated without cause on December 31, 2026, with severance benefits
Severance details are incorporated by reference from the April 3, 2026 proxy statement
Certara, Inc. said Chief Financial Officer John E. Gallagher III will resign to pursue another opportunity, with his last day expected July 14, 2026. Faiz Mohammed, the company's Senior Vice President, Finance and Treasurer since 2018, will serve as interim CFO and principal financial and accounting officer, and the company has started a search for a successor. The company also reaffirmed its 2026 financial guidance, and the filing states the resignation was not due to any disagreement with management, the board, or financial reporting matters.
CFO John E. Gallagher III tendered his resignation on June 11, 2026; he is expected to serve through July 14, 2026.
Faiz Mohammed, age 53, will become interim CFO effective July 15, 2026, and has been SVP, Finance and Treasurer since 2018.
Company reaffirmed 2026 financial guidance first given on the May 11, 2026 first-quarter earnings call.
Gallagher is expected to help with the closing process for the quarter ending June 30, 2026.
Certara reported first-quarter 2026 revenue of $106.9 million, up 1% from a year earlier, but swung to a net loss of $8.8 million from net income of $4.7 million. The company also completed the $85.0 million cash sale of its medical writing business to Veristat on May 8, 2026, and updated its full-year 2026 revenue guidance to reflect the divestiture.
Revenue was $106.9 million, up 1% from $106.0 million; software rose 7% to $49.7 million and services fell 4% to $57.2 million.
Net loss was $8.8 million, or $0.06 per diluted share, versus net income of $4.7 million, or $0.03 per diluted share, in Q1 2025; adjusted EBITDA fell to $31.7 million from $34.8 million.
Sale of the medical writing business to Veristat closed May 8, 2026, for $85.0 million cash, plus $15.0 million in escrow and up to $35.0 million in earn-out payments.
Full-year 2026 revenue guidance is $395 million to $405 million, including about $18 million from the divested business; adjusted diluted EPS guidance is $0.35 to $0.41.
Certara agreed on April 21, 2026 to sell its global medical writing and related regulatory services business to Veristat for $100 million in cash, plus up to $35 million in earn-out payments tied to the business's performance after closing. The company expects the sale to close in the second quarter of 2026 and plans to update its 2026 guidance at that time, so shareholders will not see the sale's full effect on guidance until then.
Cash consideration of $100 million, subject to post-closing adjustments for working capital, indebtedness and transaction expenses
Up to $35 million in contingent earn-out payments based on the business's financial performance after closing
Up to $15 million of the closing payment may be held in escrow if certain items are not satisfied at closing
The business generated $50 million in revenue and $17 million in adjusted EBITDA in 2025; closing is expected in the second quarter of 2026
Certara director Cynthia Collins, a Class II director who also sits on the Audit Committee, notified the company on March 27, 2026 that she will resign effective May 14, 2026, the date of the 2026 annual meeting. She said the resignation is not due to any disagreement with the company on its operations, policies or practices, and the filing reports no financial results or guidance.
Cynthia Collins notified Certara on March 27, 2026 of her intent to resign as a Class II director
Resignation takes effect May 14, 2026, the date of the 2026 annual meeting of stockholders
Collins is a member of the Board and the Audit Committee
Filing states the resignation is not the result of any disagreement with the company
Certara reported fourth-quarter 2025 revenue of $103.6 million, up 3%, but swung to a net loss of $5.9 million from net income of $6.6 million a year earlier. It also guided full-year 2026 revenue growth of 0-4% and adjusted diluted EPS of $0.44-$0.48, with adjusted EPS for 2025 at $0.44. Shareholders face flat-to-modest growth guidance and lower profit, with new CEO Jon Resnick, effective January 1, 2026, describing 2026 as a year of transition and investment.
Q4 2025 revenue was $103.6 million, up 3%; software revenue rose 10% to $46.4 million and services revenue fell 1% to $57.3 million.
Q4 2025 net loss was $5.9 million, versus net income of $6.6 million in Q4 2024; adjusted diluted EPS was $0.09, versus $0.15.
Full-year 2025 revenue was $418.8 million, up 9%; full-year adjusted diluted EPS was $0.44, versus $0.45 in 2024.
2026 guidance: revenue growth of 0-4%, adjusted EBITDA margin of 30-32%, and adjusted diluted EPS of $0.44-$0.48.
Certara appointed Jon Resnick, president of IQVIA's U.S. and Canada regional business, as chief executive officer effective January 1, 2026, succeeding William Feehery, who departs as CEO and director on December 31, 2025. Resnick also joins the board, and the company reaffirmed its 2025 full-year financial outlook, which means the leadership change does not come with a revised forecast.
Resnick receives an initial annual base salary of $750,000 and a target bonus of 100% of salary.
A make-whole restricted stock unit grant with a target value of $6,500,000 vests over the first two yearly anniversaries of the start date.
Feehery will receive a consulting fee of $20,000 per month and pro-rata vesting of equity awards granted in May 2025; either party can end the consulting arrangement with five days' notice.
The company reaffirmed its 2025 full-year financial outlook, as previously disclosed on November 6, 2025.
Certara reported third-quarter 2025 revenue of $104.6 million, up 10% from a year earlier, and swung to net income of $1.5 million from a net loss of $1.4 million. The company raised its 2025 profitability targets and narrowed full-year revenue guidance to $415 million to $420 million, though services bookings fell 9% and management cited spending hesitancy in parts of the services business.
Q3 2025 revenue was $104.6 million, up 10%; software revenue rose 22% to $43.8 million and services revenue rose 3% to $60.8 million
Q3 net income was $1.5 million, or $0.01 per diluted share, versus a net loss of $1.4 million a year earlier; adjusted EBITDA was $35.2 million, up 7%
Full-year 2025 guidance: revenue of $415 million to $420 million, adjusted EBITDA margin of about 32%, and adjusted diluted EPS of $0.45 to $0.47
Q3 services bookings were $55.8 million, down 9% year over year, mainly from softer tier-one customer trends in regulatory services
Certara, Inc. and its subsidiaries entered into a Sixth Amendment to its credit agreement on October 16, 2025, creating Replacement Term Loans that refinanced existing term loans. The company says the amendment reduces its borrowing cost and should produce interest expense savings. The filing does not state the size of the loans or the amount of savings.
Replacement Term Loans were funded in full on October 16, 2025, and used to refinance existing term loans.
Term SOFR option carries a 0.00% floor plus a 2.75% margin; ABR option carries a 1.00% floor plus a 1.75% margin.
Bank of America, N.A. is administrative agent and collateral agent; guarantees, collateral, prepayment and covenant terms are substantially similar to prior terms.
Certara reported second-quarter 2025 revenue of $104.6 million, up 12% from a year earlier, and its net loss narrowed to $2.0 million from $12.6 million. The company reiterated its full-year 2025 guidance, including revenue of $415 million to $425 million, which means the outlook was neither raised nor cut.
Revenue $104.6 million, up 12%; software revenue $46.7 million, up 22%; services revenue $57.9 million, up 5%
Net loss $2.0 million, versus $12.6 million in Q2 2024; diluted loss per share $(0.01) versus $(0.08)
Adjusted EBITDA $31.9 million, up 21% from $26.3 million
Full-year 2025 guidance reiterated: revenue $415 million to $425 million; adjusted diluted EPS $0.42 to $0.46
Certara reported first-quarter 2025 revenue of $106.0 million, up 10% from a year earlier, and net income of $4.7 million, compared with a net loss of $4.7 million in the prior-year quarter. The company reiterated its full-year 2025 guidance, including revenue of $415 million to $425 million, so shareholders have no new change to the outlook.
Revenue was $106.0 million, up 10% from $96.7 million in Q1 2024; software revenue rose 18% to $46.4 million.
Net income was $4.7 million, or $0.03 per diluted share, versus a net loss of $4.7 million in Q1 2024.
Adjusted EBITDA was $34.8 million, up 20% from $29.1 million.
Full-year 2025 guidance was reiterated: revenue of $415 million to $425 million and adjusted diluted EPS of $0.42 to $0.46.
Certara said preliminary first-quarter 2025 revenue rose 10% to $106.0 million and bookings rose 12% to $118.0 million, and its board approved a $100 million share repurchase authorization. The company reiterated its full-year 2025 guidance and said Arsenal Capital Partners agreed to a one-year lock-up on certain shares, which bars most transfers until April 14, 2026.
Preliminary Q1 2025 revenue of $106.0 million, up 10% from $96.7 million; software revenue up 18% to $46.4 million
Preliminary Q1 2025 adjusted EBITDA of $33 million to $35 million, up 13% to 20% from $29.1 million; the figures are unaudited and may change
Full-year 2025 revenue guidance of $415 million to $425 million was reiterated
Arsenal lock-up runs until April 14, 2026; the $100 million buyback may be suspended or terminated at any time
Certara said Dr. Patrick F. Smith stepped down as President of Certara Drug Development Solutions effective March 3, 2025. He will remain with the company in a senior advisory and scientific role. The filing does not name a successor or describe any change to financial results.
Dr. Patrick F. Smith stepped down as President, Certara Drug Development Solutions, effective March 3, 2025
Smith will remain employed by Certara in a senior advisory and scientific role
The filing was dated March 5, 2025 and does not name a replacement
Certara reported fourth-quarter 2024 revenue of $100.4 million, up 14% from a year earlier, and net income of $6.6 million, compared with a net loss of $12.5 million in the prior-year quarter. The company also issued full-year 2025 guidance, forecasting revenue of $415 million to $425 million and adjusted diluted EPS of $0.42 to $0.46.
Q4 2024 revenue was $100.4 million, up 14%; software revenue rose 26% to $42.3 million
Q4 2024 diluted EPS was $0.04 versus a loss of $0.08; adjusted EBITDA was $33.5 million, up 13%
2025 guidance: revenue of $415 million to $425 million and adjusted EBITDA margin of 30% to 32%
Full-year 2024 net loss narrowed to $12.1 million from $55.4 million in 2023
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Certara filing is on SEC EDGAR ↗. 8-K briefs of other companies →